Kytril

Chemotherapy, Operative Surgery, Nausea + 1 more

Treatment

3 FDA approvals

20 Active Studies for Kytril

What is Kytril

Granisetron

The Generic name of this drug

Treatment Summary

Ondansetron is a medication used to prevent nausea and vomiting in cancer patients undergoing chemotherapy. It works by blocking the action of serotonin, a chemical messenger in the brain that can trigger nausea and vomiting.

Kytril

is the brand name

Kytril Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Kytril

Granisetron

1993

63

Approved as Treatment by the FDA

Granisetron, also known as Kytril, is approved by the FDA for 3 uses such as Nausea and vomiting and Nausea .

Nausea and vomiting

Nausea

Chemotherapy

Effectiveness

How Kytril Affects Patients

Granisetron is a drug that targets serotonin receptors, specifically type 3 serotonergic receptors. It does not affect other serotonin receptors, nor does it have an effect on blood pressure, heart rate, or electrocardiogram (ECG). It works similarly to another drug called ondansetron. When chemotherapy drugs are used, they may damage the lining of the digestive tract and cause the release of serotonin. This serotonin stimulates certain nerves in the brain, leading to nausea and vomiting. Granisetron works by blocking serotonin receptors to prevent this reaction.

How Kytril works in the body

Granisetron works by blocking serotonin receptors that are present in the brain and stomach. Blocking these receptors prevents them from sending signals to the area of the brain responsible for vomiting, reducing the risk of nausea and vomiting.

When to interrupt dosage

The proposed portion of Kytril is contingent upon the determined disorder, for instance Nausea, Radiation Therapy and Operative Surgery. The amount of dosage fluctuates, as per the method of delivery (e.g. Solution - Oral or Injection, solution) detailed in the following table.

Condition

Dosage

Administration

Operative Surgery

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution, Subcutaneous, Liquid, Tablet - Oral, Tablet, Solution - Intravenous, Solution - Oral, Liquid - Intravenous, Injection - Subcutaneous

Radiation Therapy

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution, Subcutaneous, Liquid, Tablet - Oral, Tablet, Solution - Intravenous, Solution - Oral, Liquid - Intravenous, Injection - Subcutaneous

Chemotherapy

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution, Subcutaneous, Liquid, Tablet - Oral, Tablet, Solution - Intravenous, Solution - Oral, Liquid - Intravenous, Injection - Subcutaneous

Nausea

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution, Subcutaneous, Liquid, Tablet - Oral, Tablet, Solution - Intravenous, Solution - Oral, Liquid - Intravenous, Injection - Subcutaneous

Warnings

There are 20 known major drug interactions with Kytril.

Common Kytril Drug Interactions

Drug Name

Risk Level

Description

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Anagrelide.

Apomorphine

Major

The risk or severity of hypotension can be increased when Granisetron is combined with Apomorphine.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Asenapine.

Kytril Toxicity & Overdose Risk

The lowest toxic dose of this drug in rats has been found to be greater than 2000mg/kg when taken orally.

image of a doctor in a lab doing drug, clinical research

Kytril Novel Uses: Which Conditions Have a Clinical Trial Featuring Kytril?

85 active trials are currently being conducted to investigate the potential of Kytril to mitigate Nausea, Operative Surgery and Radiation Therapy.

Condition

Clinical Trials

Trial Phases

Operative Surgery

68 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2

Radiation Therapy

8 Actively Recruiting

Not Applicable, Phase 1, Phase 3, Phase 2

Nausea

0 Actively Recruiting

Chemotherapy

5 Actively Recruiting

Phase 1, Phase 3, Not Applicable, Phase 2

Kytril Reviews: What are patients saying about Kytril?

5

Patient Review

5/5/2010

Kytril for Nausea and Vomiting

This drug was a life-saver for me when I was going through chemotherapy. It completely alleviated my nausea and vomiting. I would highly recommend it to anyone else undergoing cancer treatment.

5

Patient Review

11/20/2008

Kytril for Prevent Nausea and Vomiting from Cancer Chemotherapy

This drug helped control my nausea much more than anything else I have tried. I still had no appetite but did not feel nauseous or vomit at all.

5

Patient Review

11/17/2009

Kytril for Nausea and Vomiting

This treatment has been essential for me and I can't imagine living without it.

5

Patient Review

9/18/2009

Kytril for Prevent Nausea and Vomiting from Cancer Chemotherapy

This treatment is effective.

5

Patient Review

11/18/2009

Kytril for Prevent Nausea and Vomiting from Cancer Chemotherapy

This was the only treatment that helped me with my severe vomiting and nausea when I was pregnant with my daughter. It allowed me to lead a normal life, which was a huge relief.

5

Patient Review

7/18/2020

Kytril for Nausea and Vomiting caused by Cancer Drugs

Super effective!

4.7

Patient Review

5/6/2010

Kytril for Prevent Nausea and Vomiting from Cancer Chemotherapy

This treatment has been a lifesaver. I don't know what I would do without it.

4

Patient Review

11/18/2008

Kytril for Nausea and Vomiting caused by Cancer Drugs

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kytril

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Kytril the same as Zofran?

"Glaxo's Zofran and SmithKline Beecham's Kytril are both effective in controlling chemotherapy-induced nausea and vomiting in lung cancer patients at the recommended doses."

Answered by AI

What does Kytril treat?

"This drug is used to prevent vomiting and nausea caused by cancer treatments like chemotherapy and radiation therapy. It works by blocking out serotonin, one of the body's chemicals that causes vomiting."

Answered by AI

How long does Kytril take to work?

"In the ferret animal model, a single injection of granisetron prevented vomiting due to high-dose cisplatin, or stopped vomiting within 5 to 30 seconds. In most human studies, granisetron has had little effect on blood pressure, heart rate or ECG."

Answered by AI

When should I take Kytril?

"The dosage of KYTRIL tablets for the prevention of nausea and vomiting associated with chemotherapy is typically one 2 mg tablet once a day, taken within one hour before the start of chemotherapy. This dosage may be taken for up to one week following chemotherapy."

Answered by AI

Clinical Trials for Kytril

Image of Nationwide Children's Hospital in Columbus, United States.

Handheld Ultrasound Device for Surgery

1 - 6
All Sexes
Columbus, OH

This a prospective study in pediatric patients undergoing surgery and requiring placement of an intravenous cannula. This will be a novel study to assess whether a handheld compatible cardiac ultrasound device (Lumify) can be used to quickly and reliably verify successful vascular cannulation in pediatric patients using the rapid atrial swirl sign (RASS) technique. As emerging technologies have made hand-held ultrasound devices more versatile, portable, and cheaper, it will be important to prove if they can be as accurate as traditional ultrasound devices for their intended focused point-of-care functions. If the handheld device is deemed efficacious, it will allow the use of a portable hand-held device rather than the more difficult to transport devices (Sonosite).

Waitlist Available
Has No Placebo

Nationwide Children's Hospital

Alok Moharir, MD

Have you considered Kytril clinical trials?

We made a collection of clinical trials featuring Kytril, we think they might fit your search criteria.
Go to Trials
Image of University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center in Cleveland, United States.

Music Therapy for Surgery

50 - 80
All Sexes
Cleveland, OH

Participants may take part in this study if they are scheduled to undergo a surgery that meets the following: (1) traditional open surgery via laparotomy, (2) length of surgery \>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces. The purpose of this study is (1) to evaluate the feasibility of collecting blood samples prior to surgery, post-surgery and pre- music-assisted relaxation and imagery (MARI) intervention, and immediately post-MARI intervention and (2) to identify gene expression changes associated with MARI and explore their relationship with immediate changes in pain intensity. Participants will be in this study for the duration of their hospital admission for surgery.

Waitlist Available
Has No Placebo

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Samuel N Rodgers-Melnick, PhD, MPH

Have you considered Kytril clinical trials?

We made a collection of clinical trials featuring Kytril, we think they might fit your search criteria.
Go to Trials
Image of UW Health in Madison, United States.

Automated vs Specialist-Delivered Training for Surgery

18+
All Sexes
Madison, WI

This study evaluates strategies to train surgeons to use Better Conversations, an evidence-based communication framework designed to improve informed consent by helping patients understand the goals of surgery, the downsides of treatment, and what to expect. Better Conversations supports deliberation, patient preparation, and alignment of decisions with patient goals, addressing known shortcomings in traditional informed consent. The purpose of this study is to compare two methods of surgeon training: (1) training delivered by an education specialist using audit and feedback, and (2) training supported by computerized automation that identifies elements of Better Conversations in de-identified transcripts of surgical consultations. The central question is whether the automated training program is non-inferior to the specialist-delivered program. Approximately 60 surgeons from two academic health systems will be randomized to one of these training approaches. Each surgeon will complete a didactic session, have outpatient surgical consultations audio-recorded for feedback, and complete assessment recordings after training. Patients of enrolled surgeons will complete surveys before and after their surgeon's training to evaluate patient-reported communication outcomes. Findings from this study will assess the effectiveness, feasibility, and acceptability of automated training and support the development of a larger pragmatic study to evaluate the broader effects of Better Conversations on patient outcomes.

Waitlist Available
Has No Placebo

UW Health (+1 Sites)

Margaret (Gretchen) L Schwarze, MD, MPP

Image of Nationwide Children's Hospital in Columbus, United States.

TetraGraph for Neuromuscular Blockade

Any Age
All Sexes
Columbus, OH

In most clinical instances, direct laryngoscopy and endotracheal intubation is performed after a set time (generally 60 seconds) following the administration of a neuromuscular (NM) blocking agent, rocuronium. Although the average onset time is 60 seconds, clinical studies show a standard deviation around the mean onset time of 10-20 seconds, meaning that a significant number of patients do not achieve complete NM blockade by 60 seconds. Given the above noted variability, complete NM blockade may not be achieved in 60 seconds in a significant percentage of patients, resulting in more problematic direct laryngoscopy and endotracheal intubation. Various studies have shown a higher incidence of perioperative respiratory events and postoperative concerns (sore throat, vocal cord injury) when NM blockade is not complete prior to endotracheal intubation. This study aims to use the TetraGraph monitor to clearly identify onset times of rocuronium. Additionally, whenever feasible based on the clinical needs of the case, recovery times after the single dose of rocuronium will be recorded.

Waitlist Available
Has No Placebo

Nationwide Children's Hospital

Joseph Tobias, MD

Have you considered Kytril clinical trials?

We made a collection of clinical trials featuring Kytril, we think they might fit your search criteria.
Go to Trials